The global bovine mastitis market size is projected to reach USD 1.84 billion by the end of 2027. Recent breakthrough concepts will open up the prospect of an exciting future in the global market. According to a report published by Fortune Business Insights, titled “Bovine Mastitis Market Size, Share & COVID-19 Impact Analysis, By Type (Clinical, and Sub-Clinical), By Product (Antibiotics, and Others), By Route of Administration (Intra-mammary, and Systemic), By Therapy (Lactating Period and Dry Period) and Regional Forecast, 2020-2027,” the market was worth USD 1.23 billion in 2019 and will exhibit a CAGR of 5.2% during the forecast period, 2020-2027.

For More Information:

fortunebusinessinsights.com/bovine-mastitis..

Covid-19 Pandemic has had a Minimal Impact on Market Growth; Continually Rising Demand for Dairy Products will Aid Growth

The recent coronavirus outbreak has had a minimal impact on the overall bovine mastitis market. Although lockdown and social distancing practices have shut down manufacturing units, the constant demand for dairy products has emerged in favor of the growth of the market, even during the pandemic. As these goods fall under the essential services category, the market will continue to rise at a considerable pace in the coming years.

North America Likely to Emerge Dominant; Increasing Adoption of Intra-mammary Infusion Will Aid Growth

The report analyses the latest market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge as the leading market in the coming years. The increasing adoption of intra-mammary infusion in bovine mastitis treatment will aid the growth of the regional market. The presence of large scale companies in this region will not just aid the growth of the regional market, but will also influence the growth of the global market. As of 2019, the market in North America was worth 0.40 billion and this value is projected to increase at a considerable pace in the coming years. The market in Europe will derive growth from the increasing number of company collaborations, aimed at the development of innovative treatment options for bovine mastitis in several countries including France, Germany, and the UK.